MustGrow Biologics Corp. Announces Results of Shareholder Meeting

Rhea-AI Summary

MustGrow Biologics Corp. (TSXV: MGRO, OTCQB: MGROF, FSE: 0C0) announced the outcomes of its 2024 annual shareholder meeting held on June 27, 2024. Shareholders voted to elect all director nominees listed in the management information circular dated May 28, 2024. The directors elected were Corey Giasson, Colin Bletsky, Brad Munro, Thomas Flow, Matt Kowalski, David Borecky, and Laura Westby, each receiving over 99.76% of the votes in favor.

Additionally, shareholders reappointed Ernst & Young LLP as the auditors and authorized the directors to determine their remuneration. The shareholders also reapproved the company's omnibus equity incentive plan, which is still subject to final TSX Venture Exchange approval. Detailed voting results will be available on SEDAR+.

Positive

• Shareholders overwhelmingly approved all director nominees, each receiving over 99.76% of the votes.
• Reappointment of Ernst & Young LLP as auditors was approved.
• Shareholders reapproved the company's omnibus equity incentive plan.

Negative

• The omnibus equity incentive plan is still subject to final TSX Venture Exchange approval.

Saskatoon, Saskatchewan--(Newsfile Corp. - June 27, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2024 annual meeting of shareholders (the "Meeting") held on June 27, 2024. At the Meeting, shareholders approved all director nominees listed in the Company's management information circular dated May 28, 2024 were elected as directors of the Company on a vote held by ballot. The results of the ballot were as follows:

Director	Vote Type	Number of Votes	Percentage of Votes
Corey Giasson	For	9,778,102	99.76%
	Withheld	23,200	0.24%
Colin Bletsky	For	9,778,102	99.76%
	Withheld	23,200	0.24%
Brad Munro	For	9,777,802	99.76%
	Withheld	23,500	0.24%
Thomas Flow	For	9,777,802	99.76%
	Withheld	23,500	0.24%
Matt Kowalski	For	9,778,102	99.76%
	Withheld	23,200	0.24%
David Borecky	For	9,794,002	99.93%
	Withheld	7,300	0.07%
Laura Westby	For	9,798,002	99.76%
	Withheld	3,300	0.24%

 

In addition, shareholders approved the reappointment of Ersnt & Young LLP, Chartered Professional Accountants, as the Company's auditors and authorized the directors of the Company to fix their remuneration, and reapproved the Company's omnibus equity incentive plan (the "Omnibus Plan"). Having received shareholder approval, the Company's Omnibus Plan remains subject to final approval from the TSX Venture Exchange.

The formal report on voting results with respect to all matters voted upon at the Meeting will be filed on SEDAR+ under www.sedarplus.ca.

---------

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners -- Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions' NexusBioAg -- are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow's biocontrol soil applications in Europe, Africa, and the Middle East. Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed^®) and California's Organic Input Material (OIM) Program registered biofertility product, TerraSante^TM, in key U.S. states including California. Over 150 independent tests have been completed, validating MustGrow's safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow's patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features. MustGrow has approximately 51.6 million basic common shares issued and outstanding and 54.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.

ON BEHALF OF THE BOARD

"Corey Giasson"

Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

© 2024 MustGrow Biologics Corp. All rights reserved.

MustGrow Forward-Looking Statements

Certain statements included in this press release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements are described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214771

FAQ

What were the results of MustGrow Biologics Corp.'s 2024 shareholder meeting?

All director nominees were elected with over 99.76% of votes, Ernst & Young LLP was reappointed as auditors, and the omnibus equity incentive plan was reapproved.

Who were elected as directors of MustGrow Biologics Corp.?

Corey Giasson, Colin Bletsky, Brad Munro, Thomas Flow, Matt Kowalski, David Borecky, and Laura Westby were elected as directors.

Did MustGrow Biologics Corp. shareholders approve the reappointment of auditors?

Yes, shareholders reappointed Ernst & Young LLP as auditors.

What is the status of MustGrow Biologics Corp.'s omnibus equity incentive plan?

The omnibus equity incentive plan was reapproved by shareholders but is still subject to final approval from the TSX Venture Exchange.